恩度联合TC方案治疗晚期肺癌16例疗效观察及护理

Observation on the curative effect of Endostar combined with TC scheme and nursing care in the treatment of 16 patients with advanced lung cancer

目的：探讨恩度联合TC方案（紫杉醇＋卡铂）治疗晚期肺癌的近期疗效及不良反应的护理。方法：将晚期肺癌患者31例随机分为实验组（TC＋恩度）16例和对照组15例（TC），治疗2-6疗程。按照RECIST标准和NCI—CTC标准分别评价疗效和不良反应。结果：实验组有效率为68．8％，疾病控制率为87．5％，对照组有效率为33．3％，疾病控制率为46．7％。两组比较有显著性差异（P〈0．05）。不良反应主要有白细胞下降、恶心、呕吐、脱发和心脏毒性等。这些不良反应通过对症治疗和护理后均缓解。结论：恩度联合Tc方案治疗晚期肺癌的近期客观疗效较好，不良反应较轻，患者耐受性良好。

Objective ： To investigate the short - term curative effect of Endostar combined with TC scheme and nursing care of adverse reactions in the treatment of the patients with advanced lung cancer. Methods： 31 patients with advanced lung cancer were randomly divided into experimental group （n = 16, TC plus Endostar） and control group （n = 15, single TC）. The treat- ment course was 2 weeks. The curative effect and adverse reactions were respectively evaluated according to RECIST and NCI - CTC criteria. Results： The effective rate was 68.8% and disease control rate was 87.5% in the experimental group; the effec- tive rate and disease control rate were respectively 33.3% and 46.7% in the control group. The comparison between the two groups was significant different （ P 〈 0.05 }. The adverse reactions are mainly leukopenia, nausea and vomiting, loss of hair and cardiotoxicity. These adverse reactions were eased after the adoption of appropriate treatment and nursing care. Conclusion： En- dostar combined with TC scheme has better short - term efficacy and mild adverse reaction in the treatment of advanced lung cancer and its toxicity is tolerable.